← Back to Search

Virus Therapy

Investigational drug for COVID-19

Phase 1
Waitlist Available
Research Sponsored by Oneness Biotech Co., Ltd.
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Be between 18 and 65 years old
Timeline
Screening 3 weeks
Treatment Varies
Follow Up 1 month
Awards & highlights

Study Summary

This trial tests the safety, how well tolerated it is, and how it moves through the body of a new inhalable drug for COVID-19.

Eligible Conditions
  • COVID-19

Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~1 month
This trial's timeline: 3 weeks for screening, Varies for treatment, and 1 month for reporting.

Treatment Details

Study Objectives

Outcome measures can provide a clearer picture of what you can expect from a treatment.
Primary outcome measures
Number of participants with treatment-emergent adverse events as assessed by protocol definition of AE

Trial Design

2Treatment groups
Experimental Treatment
Placebo Group
Group I: Investigational drugExperimental Treatment1 Intervention
Eligible participants will be assigned to receive 0.3-1.2 mg/kg single or multiple doses of the investigational drug.
Group II: PlaceboPlacebo Group1 Intervention
Eligible participants will be assigned to single or multiple doses of the placebo.
Treatment
First Studied
Drug Approval Stage
How many patients have taken this drug
MBS-COV
2022
Completed Phase 1
~50

Find a Location

Logistics

Participation is compensated

You will be compensated for participating in this trial.

Who is running the clinical trial?

Oneness Biotech Co., Ltd.Lead Sponsor
19 Previous Clinical Trials
1,283 Total Patients Enrolled
1 Trials studying COVID-19
135 Patients Enrolled for COVID-19

Frequently Asked Questions

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.

Does this study accept participants above the age of sixty?

"This medical trial is accepting participants from the age of majority to 55 years old."

Answered by AI

To what extent can experimental drug treatments be hazardous to patients?

"Due to the limited clinical data available, Investigational drug is given a safety rating of 1 on our internal scale. As this is only Phase 1 trials, further research needs to be conducted in order ascertain its efficacy and overall level of safety."

Answered by AI

Is this research venture open for enrollment?

"Affirmative, clinicaltrials.gov reveals that this research project is currently recruiting members. Initially posted on November 7th 2022 and last updated on January 10th 2023, the trial requires 44 individuals from one medical centre to join in their investigation."

Answered by AI

Could you provide an estimate of the number of participants currently approved for this clinical trial?

"Correct, the information on clinicaltrials.gov reveals that this trial is actively enrolling patients. It was first published on November 7th 2022 and most recently updated on January 10th 2023, with 44 participants needed from a single site."

Answered by AI

What kind of individuals is this investigation targeting?

"This investigation is searching for 44 adults aged 18-55 suffering from SARS-CoV2 infection. To be eligible, patients must agree to use two medically accepted methods of contraception if they are of childbearing potential, have normal laboratory results and ECG readings at screening, not smoke within the last 3 months, test negative for COVID-19 antigens during screening and qRT-PCR on Day -1, maintain a BMI between 18.0 - 32.0 kg/m2 (inclusive), possess no serious or chronic underlying disease which would impede study conduct or data interpretation per investigators judgement; women should also pass"

Answered by AI

Who else is applying?

What state do they live in?
California
What site did they apply to?
Phase I Unit
What portion of applicants met pre-screening criteria?
Met criteria
How many prior treatments have patients received?
0

Why did patients apply to this trial?

I want to contribute to research whenever I can.
PatientReceived 1 prior treatment
Recent research and studies
clinicaltrials.govStudy
A Phase I Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of Single and Multiple Ascending Doses of Inhaled MBS-COV (SNS812) in Healthy Participants
2022. "A Phase I Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of Single and Multiple Ascending Doses of Inhaled MBS-COV (SNS812) in Healthy Participants". ClinicalTrials.gov. https://clinicaltrials.gov/ct2/show/NCT05677893.
~18 spots leftby May 2025
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Back to top